Cellosaurus cell line U-CH1 (CVCL_4988)

• Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451).
  

PubMed=11579460; DOI=10.1002/gcc.1184
Scheil S., Bruderlein S., Liehr T., Starke H., Herms J., Schulte M., Moller P.
Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, U-CH1.
Genes Chromosomes Cancer 32:203-211(2001)

PubMed=20461036; DOI=10.1097/BRS.0b013e3181c2a8b0
Yang C., Hornicek F.J., Wood K.B., Schwab J.H., Choy E., Iafrate A.J., Rosenberg A.E., Nielsen G.P., Xavier R.J., Mankin H.J., Duan Z.-F.
Characterization and analysis of human chordoma cell lines.
Spine 35:1257-1264(2010)

PubMed=21253487; DOI=10.1155/2010/630129
Bruderlein S., Sommer J.B., Meltzer P.S., Li S.-F., Osada T., Ng D., Moller P., Alcorta D.A., Kelley M.J.
Molecular characterization of putative chordoma cell lines.
Sarcoma 2010:630129.1-630129.14(2010)

PubMed=23325432; DOI=10.1101/gr.147942.112
Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E., Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A., Crawford G.E., Absher D.M., Wold B.J., Myers R.M.
Dynamic DNA methylation across diverse human cell lines and tissues.
Genome Res. 23:555-567(2013)

PubMed=26183925; DOI=10.1158/0008-5472.CAN-14-3270
von Witzleben A., Goerttler L.T., Marienfeld R., Barth H., Lechel A., Mellert K., Bohm M., Kornmann M., Mayer-Steinacker R., von Baer A., Schultheiss M., Flanagan A.M., Moller P., Bruderlein S., Barth T.F.E.
Preclinical characterization of novel chordoma cell systems and their targeting by pharmocological inhibitors of the CDK4/6 cell-cycle pathway.
Cancer Res. 75:3823-3831(2015)

PubMed=27102572; DOI=10.1002/path.4729
Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H., Zuercher W.J., Turlais F., Ye H.-T., Leite A.P., Smith J.A., Leithner A., Moller P., Bruderlein S., Guppy N., Amary F., Tirabosco R., Strauss S.J., Pillay N., Flanagan A.M.
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
J. Pathol. 239:320-334(2016)

PubMed=28515451; DOI=10.1038/s41598-017-02174-5
Jager D., Barth T.F.E., Bruderlein S., Scheuerle A., Rinner B., von Witzleben A., Lechel A., Meyer P., Mayer-Steinacker R., von Baer A., Schultheiss M., Wirtz C.R., Moller P., Mellert K.
HOXA7, HOXA9, and HOXA10 are differentially expressed in clival and sacral chordomas.
Sci. Rep. 7:2032-2032(2017)

PubMed=28606919; DOI=10.1158/1078-0432.CCR-17-0177
Chen H., Garbutt C.C., Spentzos D., Choy E., Hornicek F.J., Duan Z.-F.
Expression and therapeutic potential of SOX9 in chordoma.
Clin. Cancer Res. 23:5176-5186(2017)

PubMed=28835717; DOI=10.1038/s41598-017-10044-3
Bosotti R., Magnaghi P., Di Bella S., Cozzi L., Cusi C., Bozzi F., Beltrami N., Carapezza G., Ballinari D., Amboldi N., Lupi R., Somaschini A., Raddrizzani L., Salom B., Galvani A., Stacchiotti S., Tamborini E., Isacchi A.
Establishment and genomic characterization of the new chordoma cell line Chor-IN-1.
Sci. Rep. 7:9226-9226(2017)